Clinical Trial Update: Reboxetine Treatment in Depressed Children and Adolescents an 8-Week, Open Study [Phase 4]

View source ↗

Summary

An 8-week, open-label Phase 4 trial evaluating the safety and efficacy of reboxetine for depression in children and adolescents.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Reboxetine (Reboxetine)

Snippet

Sponsor: Geha Mental Health Center | Conditions: Depression | Phase 4 | Status: UNKNOWN